The year in heart failure.
Tang
W H Wilson
WH
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. tangw@ccf.org
Francis
Gary S
GS
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D002307:Cardiography, Impedance; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D015897:Comorbidity; D019468:Disease Management; D017335:Enoximone / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D006439:Hemodynamics; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D020097:Natriuretic Peptide, Brain / Q000009:adverse effects / Q000627:therapeutic use; D045265:Natriuretic Peptides / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010138:Pacemaker, Artificial; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D045265:Natriuretic Peptides; D010726:Phosphodiesterase Inhibitors; D020097:Natriuretic Peptide, Brain; D009569:Nitric Oxide; D017335:Enoximone; D019001:Nitric Oxide Synthase; D014969:Xanthine Oxidase